作者:Changyou Zhou、Cheng Tang、Eric Chang、Min Ge、Songnian Lin、Eric Cline、Carina P. Tan、Yue Feng、Yun-Ping Zhou、George J. Eiermann、Aleksandr Petrov、Gino Salituro、Peter Meinke、Ralph Mosley、Taro E. Akiyama、Monica Einstein、Sanjeev Kumar、Joel Berger、Andrew D. Howard、Nancy Thornberry、Sander G. Mills、Lihu Yang
DOI:10.1016/j.bmcl.2009.10.052
日期:2010.2
Systematic structure-activity relationship (SAR) studies of a screening lead led to the discovery of a series of thiazolidinediones (TZDs) as potent GPR40 agonists. Among them, compound C demonstrated an acute mechanism-based glucose-lowering in an intraperitoneal glucose tolerance test (IPGTT) in lean mice, while no effects were observed in GPR40 knock-out mice. (C) 2010 Elsevier Ltd. All rights reserved.